Cerus, BioOne Corp. sales and marketing update

Cerus will reacquire from BioOne commercial rights to Intercept Blood System for plasma and platelets in Japan, China, Taiwan, South Korea,

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE